About me
Jorge S. Reis-Filho is the VP, Cancer Biomarker Development at AstraZeneca, whose mission is to develop mechanistically-informed but clinically-deployable biomarkers to deliver the right therapeutic agents to cancer patients at the right time during their therapeutic journey. Dr. Reis-Filho holds a joint medical degree from the University of Porto, Portugal, and the Universidade Federal do Parana, Brazil. After completing his histopathology training at the University of Porto, he did his PhD on breast cancer molecular pathology at the Institute of Cancer Research/Royal Marsden Hospital in London, UK, where he was appointed as Team Leader and subsequently the Professor and Chair of Molecular Pathology. In 2012, Dr. Reis-Filho joined Memorial Sloan Kettering Cancer Center in New York, USA, where he was appointed as Chief of Experimental Pathology and Director of the Experimental Pathology Fellowship Program in 2016. Dr. Reis-Filho has received numerous awards, including the 2010 USCAP Ramzi Cotran Young Investigator Award, the 2010 CRUK Future Leaders Prize, the 2023 BritPathSoc Goudie Medal and Lectureship, the 2023 BCRF - Larry Norton Award, and the 2024 William Gerald Award by MSKCC. He is the youngest ever Fellow of The Royal College of Pathologists to have become a member by published works. Before joining AstraZeneca, Dr. Reis-Filho was a consultant for Goldman Sachs Merchant Banking and served on the Scientific Advisory Boards or the Board of Directors of numerous biotechnology companies. Dr. Reis-Filho has published over 650 peer-reviewed articles, focused on the development of a molecular taxonomy for rare cancer types, a predictive classification for breast cancers, the causes and impact of intra-tumor genetic heterogeneity, and the development of novel technologies. At AstraZeneca, he is leading the development of computational pathology and ctDNA biomarkers for patient selection and therapeutic response prediction, and implementing AI-based solutions for patient care.
